Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nevus Count Risk Factor of BCC and Melanoma

J Am Acad Dermatol; ePub 2019 Jan 31; Wei, et al

Extremity nevus count is a helpful clinical marker in risk-stratifying individuals for basal cell carcinoma (BCC) and melanoma on all body sites, according to a recent study. Researchers evaluated prospective cohorts of 176,317 women (the Nurses' Health Study, 1986-2012 and the Nurses’ Health Study 2, 1989-2013) and 32,383 men (Health Professionals Follow-up Study, 1986-2012). Information on nevus count (none, 1-5, 6-14, ≥15) on the extremity was collected at baseline. They found:

  • There were 1,704 incident cases of melanoma, 2,296 incident cases of squamous cell carcinoma (SCC), and 30,457 incident cases of BCC, with a total of 4,655,043 person-years for melanoma and 4,267,708 person-years for keratinocyte cancers.
  • The presence of an extremity nevus was associated with an increased risk of melanoma in all anatomic areas and increased risk of BCC.
  • Individuals with ≥15 nevi had the highest risk of melanoma and BCC compared to those without any extremity nevi (melanoma hazard ratio 2.79; BCC HR 1.40).
  • No significant association was observed for SCC.
Citation:

Wei EX, Li X, Nan H. Extremity nevus count is an independent risk factor for basal cell carcinoma and melanoma, but not squamous cell carcinoma. [Published online ahead of print January 31, 2019]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.09.044.